Video

Utility of Genome-Wide Association Studies in Pediatric Oncology

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.

The monogenic and polygenic associations to subsequent breast cancer risk in survivors of childhood cancer is currently being studied using whole-genome sequencing data. Although genome-wide associated studies like this have been successful, some in the community have doubts over their clinical utility, Wang says. Although more data are needed to support a clinical recommendation, this is the first instance in which evidence to support common variant effects were found in childhood survivors of cancer.

Wang explains that using a bigger sample size gives a greater picture of what is occurring in these patients. Additionally, Wang says that this is an era in which data like these can be clinically combined with rare mutations that can explain a lot of heritable breast cancers, rather than sporadic. Science is progressing, and there is promise in finding and managing high-risk patients for screening and cancer prevention at early stages.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD